Get started
Work

Soluble programmed death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization

Year: 2019
Type: article
Study design: Observational Study
DOI: 10.1093/annonc/mdz247.065
Authors: X. Ma, X. Qu, W. Yang, H. Wang, B. Wang, M. Shen, Y. Zhou, C.Y. Zhang, Y. Sun, J. Chen, B. Hu, Z. Gong, X. Zhang, B. Pan, J. Zhou, J. Fan, X. Yang, W. Guo
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: bronze
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Boston Scientific Corporation, Taiho Pharmaceutical, EA Pharma Co., Ltd., BeiGene, Incyte, Kaken Pharmaceutical, National Natural Science Foundation of China, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Eisai, Kyowa Hakko Kirin, Astellas Pharma, Shionogi, Otsuka Pharmaceutical, Teijin Pharma, Servier, Yakult Honsha, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical, Novartis Pharma, Pfizer Japan, Chugai Pharmaceutical, Eli Lilly Japan, Bayer Yakuhin, Daiichi Sankyo Europe
OpenAlex ID: W2977479327
FWCI: 0.322
Cites:
Cited by: 2
Related to: 10